MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis
USA - NASDAQ:MLAB - US59064R1095 - Common Stock
71.89 USD
-4.13 (-5.43%)
73.5 USD
+1.61 (+2.24%)
Overall MLAB gets a fundamental rating of 4 out of 10. We evaluated MLAB against 58 industry peers in the Life Sciences Tools & Services industry. While MLAB is still in line with the averages on profitability rating, there are concerns on its financial health. MLAB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year MLAB was profitable.
MLAB had a positive operating cash flow in the past year.
In multiple years MLAB reported negative net income over the last 5 years.
Each year in the past 5 years MLAB had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -0.14%, MLAB is doing good in the industry, outperforming 65.52% of the companies in the same industry.
MLAB has a better Return On Equity (-0.36%) than 67.24% of its industry peers.
MLAB's Return On Invested Capital of 3.81% is fine compared to the rest of the industry. MLAB outperforms 65.52% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MLAB is significantly below the industry average of 13.51%.
The 3 year average ROIC (1.90%) for MLAB is below the current ROIC(3.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROIC | 3.81% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
1.3 Margins
MLAB's Operating Margin of 5.70% is fine compared to the rest of the industry. MLAB outperforms 62.07% of its industry peers.
In the last couple of years the Operating Margin of MLAB has remained more or less at the same level.
MLAB's Gross Margin of 62.12% is amongst the best of the industry. MLAB outperforms 82.76% of its industry peers.
MLAB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% |
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
Compared to 1 year ago, MLAB has more shares outstanding
The number of shares outstanding for MLAB has been increased compared to 5 years ago.
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
MLAB has an Altman-Z score of 0.83. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MLAB (0.83) is worse than 60.34% of its industry peers.
MLAB has a debt to FCF ratio of 5.38. This is a neutral value as MLAB would need 5.38 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 5.38, MLAB is doing good in the industry, outperforming 67.24% of the companies in the same industry.
MLAB has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
MLAB has a Debt to Equity ratio of 0.46. This is in the lower half of the industry: MLAB underperforms 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Altman-Z | 0.83 |
ROIC/WACC0.37
WACC10.22%
2.3 Liquidity
MLAB has a Current Ratio of 0.66. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
MLAB has a Current ratio of 0.66. This is amonst the worse of the industry: MLAB underperforms 94.83% of its industry peers.
MLAB has a Quick Ratio of 0.66. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
MLAB has a worse Quick ratio (0.47) than 94.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
The earnings per share for MLAB have decreased strongly by -98.30% in the last year.
MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
The Revenue has grown by 8.33% in the past year. This is quite good.
MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
3.2 Future
Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 231.94% on average per year.
The Revenue is expected to grow by 4.58% on average over the next years.
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 898.63 indicates a quite expensive valuation of MLAB.
MLAB's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.11. MLAB is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 46.52 indicates a quite expensive valuation of MLAB.
MLAB's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (22.55), we can say MLAB is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 898.63 | ||
| Fwd PE | 46.52 |
4.2 Price Multiples
MLAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MLAB is cheaper than 91.38% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 98.28% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.75 | ||
| EV/EBITDA | 14.3 |
4.3 Compensation for Growth
MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MLAB has a very decent profitability rating, which may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y369.85%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.84%, which is pretty low.
Compared to an average industry Dividend Yield of 0.50, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.37, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
The earnings of MLAB are negative and hence is the payout ratio. MLAB will probably not be able to sustain this dividend level.
DP-560.97%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
71.89
-4.13 (-5.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners96.24%
Inst Owner Change-7.73%
Ins Owners5.28%
Ins Owner Change6.18%
Market Cap395.39M
Revenue(TTM)242.35M
Net Income(TTM)-620000
Analysts80
Price Target90.27 (25.57%)
Short Float %6.6%
Short Ratio2.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-560.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-63.49%
Min EPS beat(2)-217.83%
Max EPS beat(2)90.84%
EPS beat(4)1
Avg EPS beat(4)-71.19%
Min EPS beat(4)-217.83%
Max EPS beat(4)90.84%
EPS beat(8)4
Avg EPS beat(8)363.88%
EPS beat(12)5
Avg EPS beat(12)215.08%
EPS beat(16)7
Avg EPS beat(16)149.42%
Revenue beat(2)0
Avg Revenue beat(2)-2.31%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-0.98%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-1.1%
Revenue beat(16)6
Avg Revenue beat(16)0.34%
PT rev (1m)0%
PT rev (3m)-26.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40%
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 898.63 | ||
| Fwd PE | 46.52 | ||
| P/S | 1.63 | ||
| P/FCF | 11.75 | ||
| P/OCF | 10.33 | ||
| P/B | 2.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.3 |
EPS(TTM)0.08
EY0.11%
EPS(NY)1.55
Fwd EY2.15%
FCF(TTM)6.12
FCFY8.51%
OCF(TTM)6.96
OCFY9.68%
SpS44.06
BVpS31.36
TBVpS-20.54
PEG (NY)0.36
PEG (5Y)N/A
Graham Number7.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROCE | 4.83% | ||
| ROIC | 3.81% | ||
| ROICexc | 4.12% | ||
| ROICexgc | N/A | ||
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% | ||
| FCFM | 13.89% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
ROICexc(3y)2.1%
ROICexc(5y)2.03%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.4%
ROCE(5y)2.02%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y106.13%
ROICexc growth 5Y21.15%
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Debt/EBITDA | 2.05 | ||
| Cap/Depr | 18.45% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.53% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.83 |
F-Score5
WACC10.22%
ROIC/WACC0.37
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
EBIT growth 1Y58.81%
EBIT growth 3Y51.48%
EBIT growth 5Y15.93%
EBIT Next Year171.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y-6.91%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-6.04%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
What is the valuation of MESA LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MESA LABORATORIES INC (MLAB) is 898.63 and the Price/Book (PB) ratio is 2.29.
How sustainable is the dividend of MESA LABORATORIES INC (MLAB) stock?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -560.97%.